Gyrus Capital Agrees to Sell Intellera to Accenture (NYSE: ACN)

Accenture To Enhance Digital Transformation Capabilities for Italy’s Public Sector with Acquisition of Intellera Consulting

MILAN, Italy, April 3, 2024 – Accenture (NYSE: ACN) has agreed to acquire Intellera Consulting, an Italian consultancy firm operating in the public administration and healthcare sectors. The acquisition aligns with Accenture’s ongoing focus on helping Italian public service organizations enhance and transform their citizen services. 

Founded in 2021, with main offices in Rome and Milan, Intellera Consulting is one of Italy’s main professional services providers, recognized for innovations within public administration, including digital, strategic, and organizational transformation processes using data and artificial intelligence. Backed by Gyrus Capital, Intellera Consulting includes a multi-disciplinary team of more than 1,400 employees working to facilitate the use of EU funds across the National Recovery and Resilience Plan (NRRP), while transforming Italy’s public service organizations via more sustainable, agile, and inclusive systems.

Mirco Dilda, Partner at Gyrus Capital, said “We are very proud to have supported Intellera Consulting in its transformation into a market-leading provider of essential digitalisation and innovation to the Italian public sector.  Delivering more efficient and cost-effective services to citizens is a key investible theme within our strategic focus on healthcare and sustainability”.  

 “Intellera Consulting is widely recognized and respected for its exceptional strategic, advisory and technology services for public administration and is an excellent fit with Accenture,” said Mauro Macchi, Chairman and Chief Executive Officer of Accenture Italia. “As we continue to focus on serving modern, responsible, citizen-oriented government, integrating new talent and skills from Intellera will expand our capabilities to deliver innovation and transformation for our public service clients.”

"Helping our clients achieve their transformation goals and offering the best professional and personal development opportunities to our colleagues are the principles that have guided us from day one; joining the Accenture network means generating incredible synergies in creating value for our clients and multiplying growth opportunities for our people," said Andrea Gabardo, Chief Executive Officer of Intellera Consulting. "Our skills, energy, and enthusiasm now have a new home and our ability to support the crucial transformation journey undertaken by the public administration, healthcare, and public services of our country has been strengthened."

The acquisition furthers Accenture’s growth strategy and focused investments in Italy, coming three months after the acquisitions of Customer Management IT and SirfinPA.

The transaction is subject to customary closing conditions.

About Gyrus

Gyrus Capital is a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus invests in businesses that address structural needs of society and the environment, and that are positioned for long-term, sustainable growth. Gyrus has a focus on complex transactions, with particular focus on corporate carve outs and entrepreneur successions in the €50 million to €500 million range. A renowned group of experienced operating partners and industry experts support Gyrus in its active investment and value-creation approach in close partnership with entrepreneurs and managers.

To learn more, please visit www.gyruscapital.com 

Advisors

Advisors to Gyrus include:  Equita & Rothschild & Co. – Financial Advisors; PedersoliGattai - Legal Due Diligence and Negotiation; OC&C – Commercial Due Diligence; New Deal Advisors – Financial and Accounting; Chiaravalli Reail & Associati - Fiscal Due Diligence; Herbert Smith Freehills – Legal Due Diligence; Studio Legale Lipani – Administrative Legal Due Diligence. 

Advisors to Management include: Allen & Overy – Legal support.

Previous
Previous

Homnya announces acquisition of Editoriale Giornalidea

Next
Next

Essential Pharma acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for the Treatment of High-Risk Neuroblastoma